Highlights
- The TAILORED-CHIP trial demonstrated that a strategy of early escalation (ticagrelor) followed by late de-escalation (clopidogrel monotherapy) did not reduce net adverse clinical events compared to standard DAPT in high-risk PCI.
- Evidence suggests the first 30 days post-PCI represent a critical ‘ischemic window’ where aspirin withdrawal may increase the risk of myocardial infarction.
- Sex-based differences are significant: men may benefit more from short-term DAPT followed by monotherapy, while women appear to favor de-escalation to clopidogrel.
- The 10-year HOST-EXAM follow-up establishes clopidogrel as a superior long-term maintenance monotherapy over aspirin following the initial DAPT phase.
Background
Percutaneous coronary intervention (PCI) for complex coronary artery disease—including left main disease, multivessel involvement, and diffuse long lesions—poses a dual challenge for clinicians. These high-risk anatomical and clinical features significantly elevate the risk of stent thrombosis (ST) and myocardial infarction (MI). Historically, this necessitated more intensive and prolonged dual antiplatelet therapy (DAPT). However, intensive therapy concurrently increases the risk of major hemorrhage, which is itself strongly associated with increased mortality.
In recent years, the concept of ‘temporal modulation’ has emerged, suggesting that antiplatelet intensity should be high during the early post-procedural phase to prevent thrombotic events and then ‘de-escalated’ once the vessel wall has stabilized to mitigate bleeding. The TAILORED-CHIP trial was designed to test a specific sequence of escalation and de-escalation in this complex patient subset, a population often underrepresented in standard abbreviated DAPT trials.
Key Content
The TAILORED-CHIP Randomized Clinical Trial
Published in the European Heart Journal (2026), the TAILORED-CHIP trial (NCT03465644) investigated whether a tailored antiplatelet strategy could improve outcomes in 2,018 patients undergoing complex high-risk PCI. The study population was notably high-risk: 22.6% underwent left main PCI, 93.7% required multivessel PCI, and 84.1% had diffuse long lesions.
Patients were randomized to:
1. Tailored Strategy: Early escalation with low-dose ticagrelor (60 mg BID) plus aspirin for less than 6 months, followed by late de-escalation to clopidogrel monotherapy for the remainder of the year.
2. Standard DAPT: Clopidogrel (75 mg daily) plus aspirin for 12 months.
At 12 months, the primary outcome—a composite of death, MI, stroke, stent thrombosis, urgent revascularization, and BARC 2, 3, or 5 bleeding—occurred in 10.5% of the tailored group versus 8.8% of the standard group (HR 1.19; 95% CI 0.90-1.58; P = .21). Crucially, the tailored-therapy group experienced significantly higher rates of clinically relevant bleeding (7.2% vs. 4.8%). The study concluded that this specific temporal modulation did not decrease net adverse events and, in fact, increased bleeding without providing additional ischemic protection.
The Critical First 30 Days: Timing of Aspirin Withdrawal
The timing of antiplatelet modulation is a subject of intense debate. While the TARGET-FIRST study suggested that aspirin discontinuation after 30 days is safe in selected patients, recent meta-analyses warn against earlier withdrawal. A systematic review of trials involving over 10,000 patients found that aspirin discontinuation within the first 30 days post-PCI was associated with a two-fold increase in the risk of MI (OR 2.12; 95% CI 1.31-3.44) without a compensatory reduction in bleeding. This reinforces the ‘ischemic vulnerability’ phase where aspirin and a P2Y12 inhibitor remain the standard of care.
Sex-Specific Outcomes in DAPT Modulation
Recent network meta-analyses (PMID: 42021393, 40643264) have identified biological sex as a critical determinant of antiplatelet efficacy and safety. In men, short-term DAPT followed by P2Y12 inhibitor monotherapy robustly reduces bleeding risk. Conversely, women—who naturally carry a higher bleeding risk—demonstrated the most favorable net clinical outcomes when de-escalated to clopidogrel rather than monotherapy. Specifically, aspirin discontinuation ranked as the optimal strategy for females, while switching P2Y12 inhibitors to clopidogrel (while potentially maintaining aspirin) appeared most effective for males. This highlights the need for a personalized approach based on sex-specific risk profiles.
Long-Term Maintenance: Clopidogrel vs. Aspirin
While much focus is placed on the first 12 months, the chronic maintenance phase remains vital. The 10-year follow-up of the HOST-EXAM trial (Lancet, 2026) provided landmark data comparing clopidogrel 75mg daily to aspirin 100mg daily in patients who remained event-free for 6-18 months post-PCI. Clopidogrel was associated with a significant reduction in the primary composite endpoint (25.4% vs 28.5%; HR 0.86; P=0.005), including both lower thrombotic and lower bleeding events. Real-world evidence from the Korean National Health Insurance Service database (18,168 patients) mirrors these findings, specifically showing clopidogrel’s superiority in preventing MI during long-term follow-up.
Antiplatelet Strategies in Specialized Subsets
Evidence is also expanding into other high-risk domains:
- Advanced Chronic Kidney Disease (CKD): The ongoing ADAPT-CKD trial is specifically evaluating whether abbreviated DAPT (<3 months) is superior to standard DAPT in patients with eGFR <45 mL/min, a group historically prone to both thrombosis and hemorrhage.
- Carotid Artery Stenting (CAS): The CHET trial is exploring whether DAPT abbreviated to 30 days followed by SAPT is non-inferior to prolonged DAPT in patients with high bleeding risk (HBR) undergoing CAS, recognizing that the anatomical substrate of the carotid differs from coronary vessels.
- Critical Care/Impella: For patients requiring microaxial flow pump support, observational data suggests that intravenous cangrelor and oral P2Y12 inhibitors yield similar safety and efficacy profiles, though cardiogenic shock remains a massive predictor of major bleeding (OR 7.09).
Expert Commentary
The neutral result of the TAILORED-CHIP trial is a significant finding for contemporary cardiology. It suggests that for patients undergoing truly complex PCI (LM disease, multi-vessel, long lesions), the standard ‘one-size-fits-all’ de-escalation may not be appropriate. The failure of the tailored group likely stems from the ‘early escalation’ phase; using ticagrelor 60 mg twice daily—even as a ‘low dose’—combined with aspirin in a population with a median age of 64 years may have pushed the bleeding threshold too high without providing a meaningful reduction in ischemic events beyond what clopidogrel already offers in the modern drug-eluting stent (DES) era.
Furthermore, the rising use of high-potency P2Y12 inhibitors (ticagrelor and prasugrel) in the US (now exceeding 45% in AMI patients) must be balanced with the clinical reality that most contemporary patients are at higher risk for bleeding than for stent thrombosis. The ISAR-REACT 5 trial’s influence is clear in the rising use of prasugrel, but TAILORED-CHIP reminds us that more ‘potent’ is not always ‘better’ in the net clinical outcome.
Mechanistically, the ‘ischemic window’ is shrinking due to improved stent scaffolds and polymer biocompatibility. This allows for earlier de-escalation, but the first 30 days remain sacrosanct for DAPT to prevent early catastrophic ST. After 30 days, the clinical focus should shift toward minimizing the ‘hemorrhagic burden.’
Conclusion
The TAILORED-CHIP trial provides a sobering reminder that complex PCI requires nuanced antiplatelet management. Temporal modulation, while conceptually sound, must be carefully calibrated; early escalation with potent agents like ticagrelor may inadvertently increase bleeding risk without a corresponding ischemic benefit in the current era of thin-strut DES. Moving forward, clinicians should prioritize the first 30 days as a period of stable DAPT, consider clopidogrel for long-term maintenance based on HOST-EXAM, and tailor strategies based on sex and specific comorbidities like CKD. Future research should focus on biomarker- or genetic-guided modulation to further refine the balance between protection and safety.
References
- Kang DY, et al. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Eur Heart J. 2026;47(17):2044-2055. PMID: 40886179.
- Kang DY, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial. Lancet. 2026;407(10537):1439-1447. PMID: 41921522.
- Valgimigli M, et al. Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-analysis. Eur Heart J. 2026;47(16):1901-1913. PMID: 40643264.
- Costa F, et al. Aspirin Withdrawal Before 30 Days After PCI in Acute Coronary Syndrome and Early Myocardial Infarction Risk: A Systematic Review and Meta-Analysis. Crit Pathw Cardiol. 2026. PMID: 42080243.
- Park DW, et al. Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial. Am Heart J. 2026;298:107437. PMID: 41932491.